Results 81 to 90 of about 91,755 (270)
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris +4 more
wiley +1 more source
Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in ...
Ken Kato +21 more
doaj +1 more source
Risk Factors for Osteoradionecrosis After Head and Neck Radiotherapy: A Systematic Review
ABSTRACT Introduction Although intensity‐modulated radiotherapy (IMRT) has led to a significant reduction in mandibular osteoradionecrosis (ORN) rates, head‐and‐neck radiotherapy (RT) is rapidly evolving—with increasing use of altered schedules and with novel systemic regimens including immune checkpoint inhibitors (ICI).
Jennifer Le Guevelou +5 more
wiley +1 more source
Clinical utility of nivolumab in the treatment of advanced melanoma
Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that ...
Yang J, Carvajal RD, Asmar R
core
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response.
Courèche-Guillaume Kaderbhai +17 more
doaj +1 more source
Corneal ulceration associated with Nivolumab use
Purpose: To describe a case of corneal ulceration associated with Nivolumab use. Observations: An 80-year-old woman treated with Nivolumab for metastatic melanoma developed an intractable corneal ulcer in her left eye, refractory to all therapies ...
Jack S. Parker +4 more
doaj +1 more source
ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index ...
Phoebe L. Sault +3 more
wiley +1 more source
Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared ...
Won‐Mook Choi +12 more
doaj +1 more source
ABSTRACT Background The role of specialist palliative care (SPC) alongside immunotherapy in head and neck cancer (HNC) is unclear. Methods This retrospective population‐based cohort study included adults with HNC who died in 2013–2021 in Alberta, Canada.
Rui Fu +12 more
wiley +1 more source
A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency
One of the novel PD-1 antibodies/immune checkpoint inhibitors, nivolumab is reported to be associated with a wide range of immune-related adverse events (irAEs). We hereby report a case of isolated adrenocorticotropic hormone (ACTH) deficiency developing
Yozo Sato +4 more
doaj +1 more source

